These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 21103255)

  • 21. Randomized trial comparing pegylated interferon alpha-2b versus pegylated interferon alpha-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients.
    Laguno M; Cifuentes C; Murillas J; Veloso S; Larrousse M; Payeras A; Bonet L; Vidal F; Milinkovic A; Bassa A; Villalonga C; Pérez I; Tural C; Martínez-Rebollar M; Calvo M; Blanco JL; Martínez E; Sánchez-Tapias JM; Gatell JM; Mallolas J
    Hepatology; 2009 Jan; 49(1):22-31. PubMed ID: 19085908
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pegylated interferon with ribavirin therapy for chronic infection with the hepatitis C virus.
    Foster GR
    Expert Opin Pharmacother; 2003 May; 4(5):685-91. PubMed ID: 12739994
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Side effect of pegylated-interferon treatment in chronic C hepatitis: agranulocytosis].
    Halász T; Farkas A; Tolvaj G; Horváth G
    Orv Hetil; 2006 Feb; 147(7):321-4. PubMed ID: 17489160
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interferon-alpha-2b plus ribavirin: a review of its use in the management of chronic hepatitis C.
    Scott LJ; Perry CM
    Drugs; 2002; 62(3):507-56. PubMed ID: 11827565
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Sarcoïdose in patient with chronic hepatitis C treated with pegylated interferon].
    Moudden MK; Ziadi T; Al Bouzidi A; Ouarssani A; Hadri L; El Baaj M
    Rev Pneumol Clin; 2014 Dec; 70(6):362-5. PubMed ID: 25131364
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Incidence of neutropenia and infections during combination treatment of chronic hepatitis C with pegylated interferon alfa-2a or alfa-2b plus ribavirin.
    Antonini MG; Babudieri S; Maida I; Baiguera C; Zanini B; Fenu L; Dettori G; Manno D; Mura MS; Carosi G; Puoti M
    Infection; 2008 Jun; 36(3):250-5. PubMed ID: 18458815
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Antiviral/immunomodulatory combination therapy: pegylated interferon alpha 2a and ribavirin in patients with chronic hepatitis C virus infection].
    Delić D; Mitrović N; Popović N; Urošević A; Pešiċ I; Simonoviċ J
    Srp Arh Celok Lek; 2012; 140(9-10):612-8. PubMed ID: 23289278
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pegylated interferon plus ribavirin combination therapy in postliver transplant recipients with recurrent hepatitis C virus infection.
    Lin TY; Yeh ML; Huang CI; Chen YL; Dai CY; Huang JF; Lin ZY; Chen SC; Huang CF; Yu ML; Chuang WL
    Kaohsiung J Med Sci; 2017 Jun; 33(6):284-289. PubMed ID: 28601232
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost Effectiveness of Daclatasvir Plus Asunaprevir Therapy for Chinese Patients with Chronic Hepatitis C Virus Genotype 1b.
    Liu Y; Wang Z; Tobe RG; Lin H; Wu B
    Clin Drug Investig; 2018 May; 38(5):427-437. PubMed ID: 29417464
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Taste disturbances during therapy with pegylated interferon-alpha 2b and ribavirin in patients with chronic hepatitis C.
    Klimacka-Nawrot E; Musialik J; Suchecka W; Petelenz M; Hartman M; Lichtański P; Błońska-Fajfrowska B
    Wiad Lek; 2010; 63(4):289-99. PubMed ID: 21608370
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacoeconomic analysis of the treatment of chronic hepatitis C with peginterferon alfa-2a or peginterferon alfa-2b plus ribavirin in Spain.
    Turnes J; Romero-Gómez M; Planas R; Solà R; García-Samaniego J; Diago M; Crespo J; Calleja JL; Rubio-Terrés C; Ventayol P
    Gastroenterol Hepatol; 2013 Nov; 36(9):555-64. PubMed ID: 24119723
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pegylated interferon alpha-2b, ribavirin and amantadine for chronic hepatitis C.
    Younossi ZM; McCullough AC; Barnes DS; Post A; Ong JP; O'Shea R; Martin LM; Bringman D; Farmer D; Levinthal G; Mullen KD; Carey WD; Tavill AS; Ferguson R; Gramlich T
    Dig Dis Sci; 2005 May; 50(5):970-5. PubMed ID: 15906777
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hydroxychloroquine augments early virological response to pegylated interferon plus ribavirin in genotype-4 chronic hepatitis C patients.
    Helal GK; Gad MA; Abd-Ellah MF; Eid MS
    J Med Virol; 2016 Dec; 88(12):2170-2178. PubMed ID: 27183377
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pegylated interferons for the treatment of chronic hepatitis C infection.
    Luxon BA; Grace M; Brassard D; Bordens R
    Clin Ther; 2002 Sep; 24(9):1363-83. PubMed ID: 12380630
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Development of sarcoidosis during treatment for chronic hepatitis C with pegylated interferon alfa-2a and ribavirin: case report and literature review].
    Cacopardo B; Pinzone MR; Nunnari G
    Infez Med; 2013 Mar; 21(1):40-44. PubMed ID: 23524900
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cutaneous sarcoidosis developing after treatment with pegylated interferon and ribavirin: a new case and review of the literature.
    López V; Molina I; Monteagudo C; Jordá E
    Int J Dermatol; 2011 Mar; 50(3):287-91. PubMed ID: 21342161
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [A case of sudden-onset hearing loss in a patient treated with peginterferon alpha-2b and ribavirin for chronic hepatitis C].
    Shin MK; Kim TH; Ju K; Ha CY; Min HJ; Jung WT; Lee OJ
    Korean J Hepatol; 2009 Sep; 15(3):370-4. PubMed ID: 19783887
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interstitial pneumonitis associated with pegylated interferon-alpha 2a and ribavirin for chronic hepatitis C infection: a case report.
    Atug O; Akin H; Alahdab YO; Ceyhan B; Tozun N; Ozdogan O
    Cases J; 2009 Mar; 2():6464. PubMed ID: 20181162
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predicting early and sustained virological responses in prior nonresponders to pegylated interferon alpha-2b plus ribavirin retreated with peginterferon alpha-2a plus ribavirin and the benefit-risk ratio of retreatment.
    Marcellin P; Craxi A; Brandao-Mello CE; Di Bisceglie AM; Andreone P; Freilich B; Rajender Reddy K; Olveira Martín A; Teuber G; Messinger D; Hooper G; Wat C; Tatsch F; Jensen DM
    J Clin Gastroenterol; 2013 Oct; 47(9):786-93. PubMed ID: 23442834
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial.
    Manns M; Marcellin P; Poordad F; de Araujo ES; Buti M; Horsmans Y; Janczewska E; Villamil F; Scott J; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Sinha R; Beumont-Mauviel M
    Lancet; 2014 Aug; 384(9941):414-26. PubMed ID: 24907224
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.